• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Nasopharyngeal Cancer - Pipeline Review, H1 2012 Product Image

Nasopharyngeal Cancer - Pipeline Review, H1 2012

  • Published: January 2012
  • 129 pages
  • Global Markets Direct

Nasopharyngeal Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Nasopharyngeal Cancer - Pipeline Review, H1 2012', provides an overview of the Nasopharyngeal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Nasopharyngeal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer. 'Nasopharyngeal Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Nasopharyngeal Cancer.
- A review of the Nasopharyngeal Cancer products under development by companies READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nasopharyngeal Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Nasopharyngeal Cancer
Nasopharyngeal Cancer Therapeutics under Development by Companies
Nasopharyngeal Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Nasopharyngeal Cancer Therapeutics – Products under Development by Companies
Nasopharyngeal Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Nasopharyngeal Cancer Therapeutics Development
F. Hoffmann-La Roche Ltd.
Sanofi-Aventis
YM BioSciences Inc.
Cyclacel Pharmaceuticals Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Biotech Pharmaceuticals Co., Ltd.
Nasopharyngeal Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Seliciclib - Drug Profile
Vorinostat + Capecitabine - Drug Profile
Cetuximab + Cisplatin + Radiotherapy - Drug Profile
Cisplatinum + Radiotherapy - Drug Profile
Xeloda + Oxaliplatin - Drug Profile
Gemcitabine + Cisplatin + Radiation Therapy - Drug Profile
Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Cisplatin + Xeloda + Radiation Therapy - Drug Profile
GW786034 - Drug Profile
Carboplatin + Paclitaxel - Drug Profile
Taxotere + Cisplatin + Radiation Therapy - Drug Profile
Taxotere + Cisplatin + 5-Fluorouracil - Drug Profile
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Docetaxel + Cisplatin - Drug Profile
Bevacizumab + Docetaxel + Cisplatin / Carboplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Radiotherapy + Cisplatin + Fluorouracil - Drug Profile
Docetaxel + Cisplatin + Fluorouracil - Drug Profile
TheraCIM - Drug Profile
Gemcitabine + Carboplatin - Drug Profile
Velcade - Drug Profile
Foscan - Drug Profile
Docetaxel + Cisplatin + 5-Fluorouracil + Radiotherapy - Drug Profile
Cisplatin + 5-Fluorouracil + Celecoxib + Radiation Therapy - Drug Profile
Cisplatin + Radiation Therapy - Drug Profile
Cisplatin + Intensity-Modulated Radiation Therapy - Drug Profile
Cisplatinum + Fluorouracil + Radiotherapy - Drug Profile
Recombinant Epstein-Barr Virus (EBV) Vaccine - Drug Profile
Paclitaxel + Carboplatin + Cisplatin + Amifostine Trihydrate + Radiation Therapy - Drug Profile
Bevacizumab + Cisplatin + Fluorouracil - Drug Profile
Cetuximab + Cisplatin + Radiation Therapy - Drug Profile
Erlotinib Hydrochloride + Radiation Therapy - Drug Profile
Adriamycin + Lomustine - Drug Profile
Amifostine Trihydrate + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Cisplatin + Radiation Therapy - Drug Profile
Nedaplatin + Radiation Therapy - Drug Profile
Modified Vaccinia Ankara Vaccine - Drug Profile
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Axitinib - Drug Profile
Sunitinib + Cisplatin + Gemcitabine - Drug Profile
Docetaxel + Cisplatin + Fluorouracil + Cetuximab + Radiation Therapy - Drug Profile
VTX-2337 + Cetuximab - Drug Profile
Nimotuzumab + Cisplatin + Radiation Therapy - Drug Profile
LBH589 + RAD001 - Drug Profile
MK2206 - Drug Profile
Cisplatin + Radiation Therapy - Drug Profile
Famitinib - Drug Profile
SOX - Drug Profile
MK-2206 - Drug Profile
Docetaxel + Cisplatin + Radiation Therapy - Drug Profile
Famitinib + Cisplatin + Radiation Therapy - Drug Profile
Nasopharyngeal Cancer Therapeutics – Drug Profile Updates
Nasopharyngeal Cancer Therapeutics – Discontinued Products
Nasopharyngeal Cancer Therapeutics - Dormant Products
Nasopharyngeal Cancer – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Nasopharyngeal Cancer, H1 2012
Products under Development for Nasopharyngeal Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
F. Hoffmann-La Roche Ltd., H1 2012
Sanofi-Aventis, H1 2012
YM BioSciences Inc., H1 2012
Cyclacel Pharmaceuticals Inc., H1 2012
Jiangsu Hengrui Medicine Co., Ltd., H1 2012
Biotech Pharmaceuticals Co., Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Nasopharyngeal Cancer Therapeutics – Drug Profile Updates
Nasopharyngeal Cancer Therapeutics – Discontinued Products
Nasopharyngeal Cancer Therapeutics – Dormant Products
Nasopharyngeal Cancer Therapeutics – Dormant Products (Contd..1)
Nasopharyngeal Cancer Therapeutics – Dormant Products (Contd..2)

List of Figures
Number of Products under Development for Nasopharyngeal Cancer, H1 2012
Products under Development for Nasopharyngeal Cancer – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos